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AbstrAct
Objective To elucidate the factors associated with 
high left ventricular mass index (LVMI) and to test the 
hypothesis that high LVMI is associated with worse 
outcome in severe aortic stenosis (AS).
Methods We analysed 3282 patients with LVMI data in 
a retrospective multicentre registry enrolling consecutive 
patients with severe AS in Japan. The management 
strategy, conservative or initial aortic valve replacement 
(AVR), was decided by the attending physician. High 
LVMI was defined as LVMI >115 g/m2 for males and 
>95 g/m2 for females. We compared the risk between 
normal and high LVMI in the primary outcome measures 
compromising aortic valve-related death and heart 
failure hospitalisation.
results Age was mean 77 (SD 9.6) years and peak 
aortic jet velocity (Vmax) was 4.1 (0.9) m/s. The factors 
associated with high LVMI (n=2374) included female, 
body mass index ≥22, absence of dyslipidemia, left 
ventricular ejection fraction <50%, Vmax ≥4 m/s, 
regurgitant valvular disease, hypertension, anaemia and 
end-stage renal disease. In the conservative management 
cohort (normal LVMI: n=691, high LVMI: n=1480), the 
excess adjusted 5-year risk of high LVMI was significant 
(HR: 1.53, 95% CI 1.26 to 1.85, p<0.001). In the 
initial AVR cohort (normal LVMI: n=217, high LVMI: 
n=894), the risk did not differ significantly between the 
two groups (HR: 0.96, 95% CI 0.60 to 1.55, p=0.88). 
There was a significant interaction between the initial 
treatment strategy and the risk of high LVMI (p=0.016).
conclusions The deleterious impact of high LVMI 
on outcome was observed in patients managed 
conservatively, but not observed in patients managed 
with initial AVR.
trial registration number UMIN000012140; Post-
results.
IntrOductIOn
Left ventricular hypertrophy (LVH) is a common 
finding in patients with cardiovascular disease 
(CVD) and having CVD risk factors.1 LVH is a 
physiological adaptation that is an attempt to 
normalise increased wall stress and to maintain 
cardiac output in hypertensive patients. However, 
this cascade of compensatory responses alters the 
myocardium, causing changes in ventricular mass as 
well as in myocardial cellular structure that lead to 
development of fibrosis.2 The presence of high left 
ventricular (LV) mass or a high left ventricular mass 
index (LVMI) is reportedly an independent predictor 
of increased cardiovascular morbidity and mortality 
both in the general populations and in hypertensive 
populations.3 Adverse consequences of LVH, such 
as myocardial ischaemia, diastolic dysfunction and 
impairment of systolic function, are related to these 
adverse cardiovascular outcomes. In patients with 
aortic stenosis (AS), the development of LVH is also 
considered as an adaptive response that maintains 
LV wall stress close to normal against the increased 
afterload due to the stenosis of the aortic valve. As 
AS gradually progresses, this afterload increases 
gradually. However, the maladaptive rather than 
beneficial effects of LVH are similarly reported in 
patients with AS.4–8 Surgical aortic valve replace-
ment (AVR) or transcatheter aortic valve implan-
tation (TAVI) in patients with severe AS results in 
regression of LV mass and a corresponding decrease 
in cardiovascular event risk.9 10 However, there are 
no previous large studies focusing on the prognostic 
impact of the LVMI in patients with severe AS strat-
ified by the initial treatment strategies managed 
either conservatively or surgically with AVR. There-
fore, it is hypothesised that a high LVMI is related to 
increased cardiovascular mortality in severe AS, and 
its prognostic impact of high LVMI differs between 
the treatment strategies. We sought to investigate 
the factors associated with a high LVMI in order 
to understand the pathophysiology of maladaptive 
responses to AS and the prognostic impact of high 
LVMI according to the initial treatment strategies in 
a large Japanese observational database of consecu-
tive patients with severe AS.
MethOds
The CURRENT AS registry (Contemporary 
outcomes after sURgery and medical tREatmeNT 
in patients with severe Aortic Stenosis registry) is 
a retrospective multicentre registry that enrolled 
consecutive patients with severe AS from 27 centres 
(the on-site surgical facilities in 20 centres) in 
Japan between January 2003 and December 2011 
(list of investigators in supplementary materials). 
We searched the hospital database for transtho-
racic echocardiography and enrolled consecutive 
patients who had met the definition of severe AS 
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(peak aortic jet velocity (Vmax) >4.0 m/s, mean aortic pressure 
gradient (PG) >40 mm Hg or aortic valve area (AVA) <1.0 cm2) 
for the first time during the study period.11 We excluded patients 
with a history of percutaneous balloon valvuloplasty or surgical 
aortic valve repair/replacement/plasty. The study design and 
patient enrolment in the registry were previously described in 
detail.12 Among the 3815 patients enrolled in the registry, the 
final study population consisted of 3282 patients whose LVMI 
had been calculated at the time of the initial echocardiography 
after excluding 533 patients due to the missing data for calcu-
lation of their LVMI (online supplementary tables 1 and 2). In 
the present analysis, we investigated the factors associated with 
high LVMI in the entire study population and compared the 
long-term clinical outcomes between the high LVMI and normal 
LVMI groups. The latter analyses were stratified according to the 
initial treatment strategies: a conservative management cohort 
of 2171 patients and an initial AVR cohort of 1111 patients 
(figure 1). The decision of the initial treatment strategy was 
based on the physicians’ discretion. Patients initially not planned 
to be treated with AVR/TAVI were assigned in the conservative 
cohort, and patients planned to be treated with AVR/TAVI were 
assigned in the initial AVR cohort. The protocol was approved 
by the institutional review board of each participating centre. 
Given the retrospective nature of the study, written informed 
consent was waived, and all of the patients agreed to participate 
in the study when contacted for follow-up. The patient record/
information was anonymised prior to analysis.
LV mass was calculated with the formula recommended by the 
American Society of Echocardiography (ASE) and was indexed 
to the body surface area as follows: LV mass=0.8×1.04 [(LVDd 
+ LVPWTd + IVSTd)3− (LVDd)3]+0.6, where LVDd was the 
LV diastolic diameter, IVSTd was the diastolic interventricular 
septal wall thickness and LVPWTd was the diastolic LV poste-
rior wall thickness.13 In line with the ASE recommendations, 
high LVMI was defined as LVMI >115 g/m2 for male patients 
and >95 g/m2 for female patients. As an additional sensitivity 
analysis, we categorised patients into four groups: no LVH, 
mild LVH, moderate LVH and severe LVH according to the 
ASE guidelines.13 The values for these groups were provided in 
supplementary methods. The data from the two-dimensional 
transthoracic echocardiography were analysed at baseline. The 
LV ejection fraction (LVEF) was measured using the Teichholz 
method or the modified Simpson’s rule method.
The primary outcome measure for the present analysis was 
a composite of the aortic valve-related death and hospitalisa-
tion for heart failure during the 5-year follow-up period. The 
secondary outcome measures included all-cause mortality as well 
as the individual components of the composite primary outcome 
measure. Aortic valve-related death included aortic proce-
dure-related death, sudden death, death caused by heart failure 
potentially related to the aortic valve and death due to aortic 
valve endocarditis. Heart failure hospitalisation was defined as 
hospitalisation for worsening heart failure requiring intravenous 
drug therapy. The cause of death was classified according to the 
Valve Academic Research Consortium definitions and was adju-
dicated by a clinical event committee.14
stAtIstIcAl AnAlysIs
The categorical variables were presented as numbers and 
percentages and were compared using a χ2 test or Fisher’s exact 
test. The continuous variables were expressed as mean (SD) or 
median (IQR). Based on their distributions, the continuous vari-
ables were compared using the Student’s t-test or the Wilcoxon 
rank sum test between two groups, and the one-way analysis 
of variance or the Kruskal-Wallis test between four groups. To 
analyse the factors associated with high LVMI, we used a multi-
variable logistic regression model involving the following poten-
tial independent clinically relevant variables: age, sex, body mass 
index (BMI), echocardiographic parameters, presence of other 
valve diseases, aetiology of AS, medical history and comorbidi-
ties, as shown in table 1. The adjusted ORs and 95% CIs were 
calculated.
Moreover, we compared the 5-year clinical outcomes between 
the high LVMI and normal LVMI groups in the conservative 
management and initial AVR cohorts according to the intention-
to-treat principle, regardless of the actual performance of AVR. 
Subgroup analyses for the primary outcome measure were also 
performed based on Vmax, LVEF and acute heart failure presen-
tation at baseline. Acute heart failure presentation was defined 
as hospitalisation for heart failure. The cumulative incidences of 
clinical events were estimated using the Kaplan-Meier method, 
and the intergroup differences were assessed with a log-rank test. 
Multivariable Cox proportional hazards models were used to 
estimate the risk of high LVMI relative to normal LVMI for the 
primary and secondary outcomes. The results were expressed 
as HRs and its 95% CIs. We selected the 22 clinically relevant 
Figure 1 Study patient flow. Normal LVMI was defined as LVMI ≤115 g/m2 for male patients and ≤95 g/m2 for female patients. AVR, aortic valve 
replacement; AS, aortic stenosis; LVMI, left ventricular mass index.
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table 1 Baseline clinical and echocardiographic characteristics in the conservative management and initial AVR cohorts
Variable All patients










Age, years*† 77.0 (9.6) 77.8 (9.6) 79.5 (9.2) <0.001 71.6 (9.4) 73.5 (8.8) 0.0051
Age ≥80 years 1378 (42) 321 (46) 787 (53) 0.0035 40 (18) 230 (26) 0.025
Male* 1275 (39) 345 (50) 457 (31) <0.001 121 (56) 352 (39) <0.001
BMI <22*‡ 1822 (56) 398 (58) 878 (59) 0.45 109 (50) 437 (49) 0.72
BSA, m2 1.46 (0.18) 1.47 (0.18) 1.42 (0.18) <0.001 1.54 (0.18) 1.49 (0.18) <0.001
Hypertension* 2326 (71) 492 (71) 1089 (74) 0.25 133 (61) 612 (68) 0.044
Current smoking* 180 (5) 31 (4) 72 (5) 0.70 15 (7) 62 (7) 0.99
Diabetes mellitus 806 (25) 187 (27) 365 (25) 0.23 58 (27) 196 (22) 0.13
On insulin therapy* 177 (5) 41 (6) 82 (6) 0.71 12 (6) 42 (5) 0.61
Coronary artery disease* 1036 (32) 231 (33) 441 (30) 0.088 78 (36) 286 (32) 0.27
Prior symptomatic stroke* 428 (13) 119 (17) 209 (14) 0.060 22 (10) 78 (9) 0.51
Atrial fibrillation or flutter*† 698 (21) 157 (23) 351 (24) 0.61 43 (20) 147 (16) 0.24
Serum creatinine, mg/dL* 0.9 (0.56) 0.89
(0.7–1.22)
0.91 (0.7–1.49) <0.001 0.79 (0.65–0.97) 0.83 (0.69–
1.16)
0.022
ESRD*§ 486 (15) 77 (11) 270 (18) <0.001 16 (7) 123 (14) 0.011
Anaemia*¶ 1784 (54) 333 (48) 873 (59) <0.001 93 (43) 485 (54) 0.0026
Liver cirrhosis (Child-Pugh B or C)* 34 (1) 6 (1) 22 (1) 0.23 0 (0) 6 (0.7) 0.60
Malignancy currently under treatment*† 133 (4) 53 (8) 57 (4) <0.001 2 (1) 21 (2) 0.29
Chronic lung disease (moderate or severe)* 97 (3) 21 (3) 57 (4) 0.34 2 (1) 17 (2) 0.56









Symptoms at index echocardiography 1707 (52) 181 (26) 690 (47) <0.001 147 (68) 689 (77) 0.0039
Chest pain 439 (13) 46 (7) 120 (8) 0.23 60 (28) 213 (24) 0.25
Syncope 173 (5) 18 (3) 51 (3) 0.29 26 (12) 78 (9) 0.15
Chronic exertional dyspnoea 1353 (41) 147 (21) 601 (41) <0.001 84 (39) 521(58) <0.001
Admission for heart failure at index echocardiography*† 621 (19) 66 (10) 318 (21) <0.001 21 (10) 216 (24) <0.001
Echocardiographic variables
Vmax, m/s 4.1 (0.9) 3.6 (0.7) 4.0 (0.9) <0.001 4.4 (0.7) 4.8 (0.8) <0.001
Vmax >4 m/s*† 1863 (57) 204 (30) 740 (50) <0.001 165 (76) 754 (84) 0.0037
Peak aortic PG, mm Hg 72 (32) 53 (20) 66 (29) <0.001 80 (25) 94 (33) <0.001
Mean aortic PG, mm Hg 41 (20) 30 (12) 38 (18) <0.001 47 (16) 56 (20) <0.001
AVA (equation of continuity), cm2 0.72 (0.18) 0.80 (0.14) 0.74 (0.19) <0.001 0.69 (0.16) 0.64 (0.18) <0.001
Low gradient AS** 1215 (37) 426 (62) 645(44) <0.001 41 (19) 103 (12) 0.0029
Low gradient AS with preserved LVEF†† 966 (29) 377 (55) 491 (33) <0.001 37 (17) 61 (7) <0.001
AVA index, cm2/m2 0.50 (0.13) 0.55 (0.11) 0.52 (0.13) <0.001 0.46 (0.11) 0.43 (0.12) 0.011
LV end-diastolic diameter, mm 46.1 (7.0) 42.3 (5.5) 47.1 (6.7) <0.001 42.5 (5.1) 48.4 (7.2) <0.001
LV end-systolic diameter, mm 30.3 (7.9) 27.2 (5.8) 31.2 (7.9) <0.001 26.1 (5.5) 32.3 (8.7) <0.001
LVEF, % 63 (13) 65 (11) 62 (14) <0.001 69 (9) 62 (14) <0.001
LVEF <68%*† 1928 (59) 393 (57) 919 (62) 0.021 92 (42) 524 (59) <0.001
LVMI, g/m2 123 (101–151) 89 (79–99) 133 (117–157) <0.001 91 (82–100) 145 (124–206) <0.001
Any combined valvular disease (moderate or severe)*† 1310 (40) 199 (29) 662 (45) <0.001 60 (28) 389 (44) <0.001
TR pressure gradient ≥40 mm Hg* 516 (16) 79 (11) 269 (18) <0.001 16 (7) 152 (17) <0.001
p Values were calculated from a χ2 test or Fisher’s exact test for categorical variables, and Student’s t-test or Wilcoxon rank sum test for continuous variables.
Values are number (%), mean (SD) or median (IQR).
*Potential risk-adjusting variables selected for Cox proportional hazard models.
†Potential risk-adjusting variables selected for parsimonious Cox proportional hazard models.
‡BMI was calculated as weight in kilograms divided by height in metres squared.
§ESRD was defined as creatinine level >2 mg/dL and/or haemodialysis.
¶Anaemia was defined by the WHO criteria (haemoglobin <12.0 g/dL in women and <13.0 g/dL in men).
**Low gradient AS=AVA<1 cm2, mean PG ≤40 mm Hg and Vmax ≤4 m/s.
††Low gradient AS with preserved LVEF=AVA <1 cm2, mean PG ≤40 mm Hg, Vmax ≤4 m/s and LVEF ≥50%.
AS, aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement; BMI, body mass index; BSA, body surface area; ESRD, end-stage renal disease; LV, left ventricular; 
LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; PG, pressure gradient; PROM, predicted risk of mortality; STS, Society of Thoracic Surgeons; TR, tricuspid 
regurgitation; Vmax, peak aortic jet velocity.
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risk-adjusting variables presented in table 1 for the primary 
outcome measure and all-cause mortality in the main analysis, 
with the centres incorporated as the stratification variable. This 
was consistent with our previous report,12 except for the addi-
tion of acute heart failure presentation as a risk-adjusting vari-
able. Given the small number of patients with an event, we used 
the seven clinically relevant risk-adjusting variables presented in 
table 1 for aortic valve death, heart failure hospitalisation and 
for the additional analysis of four LVH classifications. Propor-
tional hazard assumptions for the normal LVMI and high LVMI 
groups were assessed on the plots of log (time) versus log [−log 
(survival)] stratified by the variable, and verified to be acceptable, 
as well as other risk-adjusting variables previously verified.12 
We also evaluated the interaction between the initial treatment 
strategies and the effect of high LVMI relative to normal LVMI 
for the clinical outcomes. In the subgroup analysis, we used 21 
risk-adjusting variables in the conservative management cohort, 
and six risk-adjusting variables in the initial AVR cohort, without 
adjustment for multiple tests. We also evaluated the interactions 
between the subgroup factors and the effect of high LVMI rela-
tive to normal LVMI for the clinical outcomes.
All the statistical analyses were conducted by physicians 
(EM, TT and TK) and a statistician (TM) using JMP V.10.0.2 
or SAS V.9.4. All the reported p values were two tailed, and p 
values <0.05 were considered statistically significant.
results
Factors associated with high lVMI
A total of 2374 patients (1480 patients in the conservative 
management cohort and 894 patients in the initial AVR cohort) 
had high LVMI, and 908 patients (691 patients in the conser-
vative management cohort and 217 patients in the initial AVR 
cohort) had normal LVMI (figure 1). The baseline characteristics 
of the entire study population are presented in online supple-
mentary table 3. According to the multivariable logistic regres-
sion analysis, the female sex, LVEF <50%, Vmax ≥4 m/s, aortic 
regurgitation, mitral regurgitation, hypertension, anaemia and 
end-stage renal disease (serum creatinine >2 mg/dL or haemo-
dialysis) were independent factors associated with high LVMI, 
while dyslipidemia and a BMI <22 were independent negative 
factors associated with high LVMI (figure 2).
baseline clinical and echocardiographic characteristics: 
normal versus high lVMI groups
The differences in the baseline clinical and echocardiographic 
characteristics of the high and normal LVMI groups were generally 
consistent in both the conservative management and initial AVR 
cohorts (table 1 and online supplementary table 4). The patients in 
the high LVMI group were older than those in the normal LVMI 
group, were more often female and were more likely to have a 
smaller body surface area, hypertension, end-stage renal disease, 
anaemia, higher surgical risk scores, symptoms, greater severity of 
AS, larger LV dimensions, lower LVEF, greater LV wall thickness, 
combined valvular disease and pulmonary hypertension (table 1 
and online supplementary table 4).
clinical outcomes: normal versus high lVMI groups
The median follow-up duration after the index echocardiog-
raphy was 1204 (IQR: 824) days, with a 94% follow-up rate 
Figure 2 Multivariable logistic regression analysis for the factors associated with high LVMI. LVMI=left ventricular mass index. || BMI was 
calculated as weight in kilograms divided by height in metres squared. † Dyslipidemia was defined as total cholesterol levels ≥240 mg/dL, high-
density lipoprotein cholesterol levels <40 g/dL or the use of statin. ‡ ESRD was defined as creatinine level >2 mg/dL and/or haemodialysis.   
§ Anaemia was defined by the WHO criteria (haemoglobin <12.0 g/dL in women and <13.0 g/dL in men). AR, aortic regurgitation; BMI, body mass 
index; CABG, coronary artery bypass grafting; ESRD, end-stage renal disease; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; 
MR, mitral regurgitation; MS, mitral stenosis; PCI, percutaneous coronary intervention; TR, tricuspid regurgitation; Vmax, peak aortic jet velocity.
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at 2 years. The cumulative 5-year incidence of surgical AVR or 
TAVI was significantly higher in the high LVMI group than in the 
normal LVMI group in both the conservative management and 
initial AVR cohorts (figure 3A and B).
In the conservative management cohort, the cumulative 5-year 
incidences of the primary and secondary outcome measures 
were significantly higher in the high LVMI group than in the 
normal LVMI group (table 2 and figure 4A). After adjusting for 
confounders, the excess risk of high LVMI relative to normal 
LVMI for the primary outcome measure was remained signifi-
cant in the conservative management cohort. The adjusted risk 
for all-cause death did not differ significantly between high and 
normal LMI groups (table 2).
In the initial AVR cohort, the cumulative 5-year incidence 
of the primary outcome did not differ significantly between 
the high and normal LVMI groups (table 2 and figure 4B). 
After adjusting for confounders, the risks for the primary and 
secondary outcomes did not differ significantly between the high 
and normal LVMI groups in the initial AVR cohort (table 2). 
There was a significant interaction between the initial treatment 
strategies and the effect of high LVMI relative to normal LVMI 
for the primary outcome measure (table 2).
When the severity of LVH was classified into four groups 
(online supplementary table 5), the increasing LVMI was associ-
ated with incrementally higher risk for primary outcome measures 
(online supplementary figure 1 and online supplementary table 
6). There was a significant interaction between initial treatment 
strategies and the effect of LVH severity on the primary outcome 
measure (interaction p=0.034 and online supplementary table 6).
subgroup analysis in the conservative management and 
initial AVr cohorts: normal versus high lVMI groups
In the subgroup analyses stratified by Vmax and LVEF, there were 
no significant interactions between the subgroup factors and the 
effect of high LVMI for the primary outcome measure in both the 
conservative management and initial AVR cohorts (online supple-
mentary table 7). There was a significant interaction between acute 
heart failure presentation and the effect of high LVMI for the 
primary outcome measure in the conservative management cohort 
(p<0.001, online supplementary table 7).
dIscussIOn
The main finding of this study are the following: (1) female 
sex, BMI ≥22, low LVEF, severity of AS, valvular regurgitation, 
hypertension, anaemia, absence of dyslipidemia and renal 
dysfunction were independently associated with high LVMI in 
patients with severe AS. (2) The deleterious impact of LVMI 
on the outcomes found in patients with conservative treatment 
had in contrast no effect on the outcomes in patients who were 
managed with AVR or TAVI.
The underlying mechanisms of development of LVH are 
multifactorial in hypertensive patients, although the traditional 
theory was hypertrophy for adaptation.15
Several studies have shown that the degree of LVH is poorly 
related the severity of flow obstruction in AS.5 The previously 
reported factors influencing the LV response in addition to the pres-
sure overload include age,16 sex,17 and obesity18 in patients with AS 
and diabetes,19 and kidney disease20 in patients who underwent 
surgical AVR or TAVI. Other factors associated with high LVMI 
remain unknown in patients with severe AS. Among the factors 
associated with increased LVMI in the present study, hyperten-
sion, concomitant valvular regurgitation, greater peak aortic valve 
gradient, anaemia and kidney dysfunction are the chronic factors 
that increase the afterload and cardiac workload through hemo-
dynamics. Female sex is one factor associated with the increased 
LVMI. Previous studies have reported that there was no signifi-
cant difference in the rate of progression of AS between male 
and female patients.21 Therefore, the noted difference in LVMI is 
more likely to be influenced by the differences in the ventricular 
response. Women are usually less prone to myocardial hypertrophy, 
mainly because of the protective effects of oestrogen on cardio-
myocytes and fibroblasts.22 However, female sex is an increased 
risk of myocardial hypertrophy caused by hypertensive stress after 
menopause.23 This study showed that LVEF <50% was associated 
with high LVMI. A recent study has suggested that increased LV 
mass is a predictor of LV dysfunction, although a causal relation-
ship between low LVEF and high LVMI was not determined in the 
present study.5 The present study demonstrated that dyslipidemia 
was a negative factor associated with high LVMI. Dyslipidemia was 
defined based on total cholesterol levels ≥240 mg/dL, high-den-
sity lipoprotein cholesterol levels <40 g/dL or the use of statin in 
CURRENT AS registry. Statins have been demonstrated to decrease 
LVMI in hypertensive patients.24 It is proposed that its mechanism 
is related to the cholesterol-independent beneficial effects induced 
by anti-inflammatory mechanisms.25 In this study, 74% of the 
patients (903/1226) received statin therapy (online supplementary 
table 4).
Figure 3 Cumulative incidence of surgical AVR or TAVI during follow-up: normal versus high LVMI groups. (A) Conservative management cohort and 
(B) initial AVR cohort. AVR, aortic valve replacement; LVMI, left ventricular mass index; TAVI, transcatheter aortic valve implantation.
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High LVMI adversely affected the outcomes of patients 
with severe AS, when managed conservatively. This finding is 
consistent with that of previous studies. High LVMI is inde-
pendently associated with increased cardiovascular mortality in 
1656 asymptomatic patients with mild to moderate AS4 and in 
201 asymptomatic patients with severe AS6 under conservative 
management. We analysed 3282 consecutive patients with severe 
AS stratified by the initial treatment strategies, demonstrating 
that high LVMI as compared with normal LVMI was associated 
with higher risk for long-term AS-related clinical outcomes in 
patients managed conservatively, but not in patients managed 
with the initial AVR strategy.
Risk prediction in severe AS before the development of 
congestive heart failure remains a challenge. Echocardiographic 
markers for developing symptoms or death are aortic valve calci-
fication, a rapid increase in the PG, very high aortic valve veloc-
ities,26 LVEF <50%10 and other echocardiographic parameters8 
as well as LV hypertrophy.4 6 7 In the present study, high LVMI, 
regardless of the severity of Vmax, was associated with an excess 
risk for the long-term AS-related outcomes and would be an 
additional risk predictor beyond Vmax in patients with severe 
AS managed conservatively.
In contrast, high LVMI did not have any adverse impact on 
long-term AS-related outcomes in patients managed surgically. 
There is no previous study about the relationship between preop-
erative LVMI and postoperative outcomes. However, surgical 
AVR and TAVI were reported to reduce postoperative LVMI 
during follow-up.9 10 This effect is called reverse remodelling of 
LVH after AVR. Early reverse remodelling is thought to be due 
to the regression of myocyte hypertrophy after the decrease of 
afterload,4 and its late regression is a consequence of remodel-
ling of the interstitial fibrosis, which may develop over years.27 
In addition, the sooner the regression of LVMI was observed, 
the better outcome was observed.9 One of the reasons for having 
no effect of high LVMI on the prognosis after AVR might be 
related with a line of evidence suggesting that the higher preop-
erative LVMI is a correlate of maximum LV mass regression 
after AVR.10 The no effect of high LVMI was in contrast to the 
adverse impact of LV dysfunction on postoperative prognosis, 
although it remains unclear what matters most among the factors 
such as low LVEF,10 low gradient or/and low flow28 in patients 
with severe AS managed with surgical AVR or TAVI.
lIMItAtIOns
This study has several limitations. First, this retrospective study was 
performed without randomisation of patient selection. Therefore, 
the decision on the initial treatment strategy was based on physi-
cian discretion. Second, the echocardiographic measurement was 
not performed in a core laboratory but in each participating centre. 
Therefore, we could not deny the possibility for variations in the 
echocardiographic measurement of LVMI or LVEF. Third, infor-
mation about the cardiac output and stress echocardiography was 
not collected in this study. In clinical practice, a variable propor-
tion of patients with severe AS on the basis of AVA <1.0 cm2 
alone by echocardiography have less severe Vmax and/or mean 
PG (low gradient severe AS).29 A large proportion of patients 
with preserved EF were included in the normal LVMI group, and 
they might have small ventricular cavities, increased afterload and 
subtle systolic dysfunction with cardiac fibrosis.30 The informa-
tion about cardiac output would help for the understanding of the 
pathophysiology. Forth, we did not analyse the changes in LVMI 
and LVEF during follow-up, and therefore, we could not assess the 
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long-term outcomes. Fifth, there remain unmeasured confounders 
affecting the long-term prognosis, although we conducted exten-
sive statistical adjustment for the measured confounders. Sthix, 
several subgroup analyses have a risk for multiple comparison 
as well as small sample size with low statistical power. Finally, 
missing data included the aged patients with fewer comorbidities 
and higher EuroSCOREs (European System for Cardiac Operative 
Risk Evalution).
cOnclusIOns
In patients with severe AS managed conservatively, high LVMI as 
compared with normal LVMI was associated with higher long-
term risk for AS-related clinical events, while high LVMI relative 
to normal LVMI did not have effect in patients managed with 
initial AVR.
Author affiliations
1Department of Cardiovascular Medicine, Kyoto University graduate School of 
Medicine, Kyoto, Japan
2Department of Clinical epidemiology, Hyogo College of Medicine, Nishinomiya, 
Japan
3Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano 
Hospital, Osaka, Japan
4Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan
5Department of Cardiovascular Medicine, Kobe City Medical Center general Hospital, 
Kobe, Japan
6Department of Cardiology, Tenri Hospital, Tenri, Japan
7Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
8Department of Cardiology, Kansai electric Power Hospital, Osaka, Japan
9Department of Cardiovascular Surgery, Kobe City Medical Center general Hospital, 
Kobe, Japan
10Department of Cardiovascular Surgery, Kyoto University graduate School of 
Medicine, Kyoto, Japan
contributors TakaK had full access to all the data in the study and takes 
responsibility for the integrity of the data and the accuracy of the data analysis. 
Study concept and design: eM-M, TakaK, TM, TT and TakeK. Acquisition, analysis or 
interpretation of data: all authors. Drafting of the manuscript: eM-M, TakaK, TM and 
TK. Critical revision of the manuscript for important intellectual content: all authors. 
Statistical analysis: eM-M, TakaK, TM and TT. Administrative, technical or material 
support: TK. Study supervision: TM and TK.
competing interests None declared.
ethics approval The institutional review board of Kyoto University and each 
participating centre.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
reFerences
 1 Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and 
geometry to morbidity and mortality in uncomplicated essential hypertension. Ann 
Intern Med 1991;114:345–52.
 2 Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and 
prognosis. Circulation 2000;102:470–9.
 3 Verdecchia P, Porcellati C, Reboldi g, et al. Left ventricular hypertrophy as an 
independent predictor of acute cerebrovascular events in essential hypertension. 
Circulation 2001;104:2039–44.
Key messages
What is already known on this subject?
Several factors, including age, sex, obesity, diabetes and 
kidney disease influence the left ventricular (LV) hypertrophy 
in patients with aortic stenosis (AS). A high left ventricular 
mass index (LVMI) is associated with increased mortality in 
asymptomatic patients with mild to moderate AS who were 
managed conservatively.
What might this study add?
Female sex, low ejection fraction, severity of AS, valvular 
regurgitation, hypertension, anaemia, absence of dyslipidemia 
and renal dysfunction were independently associated with high 
LVMI in patients with severe AS. The deleterious impact of high 
LVMI on the outcomes found in patients with conservative 
treatment had in contrast no effect on the outcomes in patients 
who were managed surgically.
how might this impact on clinical practice?
Considering the different effects of high LVMI on outcomes 
between treatment strategies, ventricular response is important 
for the risk stratification and the timing of surgical or 
transcatheter intervention in patients with severe AS.
Figure 4 Cumulative incidence of the primary outcome measure (a composite of aortic valve-related death or hospitalisation due to heart failure): 
normal versus high LVMI groups. (A) Conservative management cohort and (B) initial AVR cohort. AVR, aortic valve replacement; LVMI, left ventricular 
mass index.
group.bmj.com on December 4, 2017 - Published by http://heart.bmj.com/Downloaded from 
1999Minamino-Muta e, et al. Heart 2017;103:1992–1999. doi:10.1136/heartjnl-2016-311022
Aortic and vascular disease
 4 gerdts e, Rossebø AB, Pedersen TR, et al. Relation of left ventricular mass to Prognosis 
in initially asymptomatic mild to moderate aortic valve Stenosis. Circ Cardiovasc 
Imaging 2015;8:e003644.
 5 Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve Stenosis: 
preventive or promotive of systolic dysfunction and heart failure? Eur Heart J 
2005;26:1790–6.
 6 Cioffi g, Faggiano P, Vizzardi e, et al. Prognostic effect of inappropriately high left 
ventricular mass in asymptomatic severe aortic Stenosis. Heart  
2011;97:301–7.
 7 Pellikka PA, Sarano Me, Nishimura RA, et al. Outcome of 622 adults with 
asymptomatic, hemodynamically significant aortic Stenosis during prolonged follow-
up. Circulation 2005;111:3290–5.
 8 Hachicha Z, Dumesnil Jg, Pibarot P. Usefulness of the valvuloarterial impedance 
to predict adverse outcome in asymptomatic aortic Stenosis. J Am Coll Cardiol 
2009;54:1003–11.
 9 Lindman BR, Stewart WJ, Pibarot P, et al. early regression of severe left ventricular 
hypertrophy after transcatheter aortic valve replacement is associated with decreased 
hospitalizations. JACC Cardiovasc Interv 2014;7:662–73.
 10 Une D, Mesana L, Chan V, et al. Clinical impact of changes in left ventricular function 
after aortic valve replacement: analysis from 3112 patients. Circulation  
2015;132:741–7.
 11 Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the 
management of patients with Valvular Heart disease: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice guidelines. 
Circulation 2014;129:e521–e643.
 12 Taniguchi T, Morimoto T, Shiomi H, et al. Initial Surgical Versus Conservative 
strategies in patients with asymptomatic severe aortic Stenosis. J Am Coll Cardiol 
2015;66:2827–38.
 13 Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber 
quantification by echocardiography in adults: an update from the American Society of 
echocardiography and the european Association of Cardiovascular Imaging. J Am Soc 
Echocardiogr 2015;28:1–39. e14..
 14 Kappetein AP, Head SJ, généreux P, et al. Updated standardized endpoint 
definitions for transcatheter aortic valve implantation: the Valve Academic Research 
Consortium-2 consensus document. J Am Coll Cardiol  
2012;60:1438–54.
 15 Peer M, Boaz M, Zipora M, et al. Determinants of left ventricular hypertrophy in 
hypertensive patients: identification of high-risk patients by metabolic, vascular, and 
inflammatory risk factors. Int J Angiol 2013;22:223–8.
 16 Salcedo ee, Korzick DH, Currie PJ, et al. Determinants of left ventricular hypertrophy in 
patients with aortic Stenosis. Cleve Clin J Med 1989;56:590–6.
 17 Lee JM, Park SJ, Lee SP, et al. gender difference in ventricular response to 
aortic Stenosis: insight from cardiovascular magnetic resonance. PLoS One 
2015;10:e0121684.
 18 Lund BP, gohlke-Bärwolf C, Cramariuc D, et al. effect of obesity on left ventricular 
mass and systolic function in patients with asymptomatic aortic Stenosis 
(a Simvastatin ezetimibe in aortic Stenosis [SeAS] substudy). Am J Cardiol 
2010;105:1456–60.
 19 Nakamura T, Toda K, Kuratani T, et al. Diabetes Mellitus impairs left ventricular mass 
regression after Surgical or Transcatheter aortic valve replacement for severe aortic 
Stenosis. Heart Lung Circ 2016;25:68–74.
 20 Benedetto U, Melina g, Angeloni e, et al. Moderate chronic kidney disease and left 
ventricular hypertrophy after aortic valve replacement for aortic valve Stenosis. J 
Thorac Cardiovasc Surg 2010;139:881–6.
 21 Otto CM, Burwash Ig, Legget Me, et al. Prospective study of asymptomatic valvular 
aortic Stenosis. clinical, echocardiographic, and exercise predictors of outcome. 
Circulation 1997;95:2262–70.
 22 Fazal L, Azibani F, Vodovar N, et al. effects of biological sex on the pathophysiology of 
the heart. Br J Pharmacol 2014;171:555–66.
 23 Luczak eD, Leinwand LA. Sex-based cardiac physiology. Annu Rev Physiol 
2009;71:1–18.
 24 Warita S, Kawasaki M, Tanaka R, et al. effects of pitavastatin on cardiac structure 
and function and on prevention of atrial fibrillation in elderly hypertensive patients: a 
prospective study of 2-years’ follow-up. Circ J 2012;76:2755–62.
 25 Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing 
cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429–37.
 26 Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic 
Stenosis. Circulation 2010;121:151–6.
 27 Bjørnstad JL, Neverdal NO, Vengen OA, et al. Alterations in circulating activin A, 
gDF-15, TgF-beta3 and MMP-2, -3, and -9 during one year of left ventricular 
reverse remodelling in patients operated for severe aortic Stenosis. Eur J Heart Fail 
2008;10:1201–7.
 28 Herrmann HC, Pibarot P, Hueter I, et al. Predictors of mortality and outcomes of 
therapy in low-flow severe aortic Stenosis: a Placement of aortic transcatheter valves 
(PARTNeR) trial analysis. Circulation 2013;127:2316–26.
 29 Clavel MA, Magne J, Pibarot P. Low-gradient aortic stenosis. Eur Heart J 
2016;37:2645–57.
 30 Hachicha Z, Dumesnil Jg, Bogaty P, et al. Paradoxical low-flow, low-gradient severe 
aortic Stenosis despite preserved ejection fraction is associated with higher afterload 
and reduced survival. Circulation 2007;115:2856–64.
group.bmj.com on December 4, 2017 - Published by http://heart.bmj.com/Downloaded from 
the outcomes of severe aortic stenosis
Impact of the left ventricular mass index on
Kenji Minatoya and Takeshi Kimura
Tada, Akihiro Komasa, Katsuhisa Ishii, Naritatsu Saito, Ryuzo Sakata, 
Shirai, Takeshi Kitai, Chisato Izumi, Kazuya Nagao, Tsukasa Inada, Eiji
Nakane, Kenichi Sasaki, Moritoshi Funasako, Koji Ueyama, Shinichi 
EisakuMoriaki Inoko, Tetsuya Haruna, Toshiaki Izumi, Shoichi Miyamoto, 
Eri Minamino-Muta, Takao Kato, Takeshi Morimoto, Tomohiko Taniguchi,
doi: 10.1136/heartjnl-2016-311022
2017 103: 1992-1999 originally published online July 6, 2017Heart 
 http://heart.bmj.com/content/103/24/1992




This article cites 30 articles, 16 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on December 4, 2017 - Published by http://heart.bmj.com/Downloaded from 
